<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02100176</url>
  </required_header>
  <id_info>
    <org_study_id>MIRT-RT</org_study_id>
    <secondary_id>MIRT-RT</secondary_id>
    <nct_id>NCT02100176</nct_id>
  </id_info>
  <brief_title>MIRT and Rotigotine in the Early Stage of PD</brief_title>
  <acronym>MIRT-RT</acronym>
  <official_title>Multidisciplinary Intensive Rehabilitation Treatment and Rotigotine in the Early Stages of Parkinson's Disease: a Randomized Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Generale Di Zona Moriggia-Pelascini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale Generale Di Zona Moriggia-Pelascini</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test whether a multidisciplinary intensive rehabilitation treatment (MIRT) slowed down the
      progression of the disease in Parkinson's disease (PD) &quot;de novo&quot; patients, all treated with
      Rotigotine, in a randomized controlled study with a 18 months follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the last years different rehabilitation treatments have been proposed to address specific
      motor deficits in Parkinson's disease. Nevertheless, the evidence of a possible
      neuroprotective action of exercise in PD has been obscured by the facts that all studies were
      performed in patients in different disease stages and under a variety of pharmacological
      treatments. Our objective is to test whether a multidisciplinary intensive rehabilitation
      treatment (MIRT) slowed down the progression of the disease in PD &quot;de novo&quot; patients, all
      treated with Rotigotine, in a randomized controlled study with a 18 months follow-up.

      40 Patients at the initial stages of PD (H&amp;Y stages 1,5-2) treated only with Rotigotine will
      be enrolled and randomly assigne into two groups. Patients in group 1 (20 subjects) will be
      undergone 2 MIRT cycle (at T0 and T3). MIRT consist of a 4-week cycle of physiotherapy that
      entailed three daily sessions 5 days a week (Frazzitta G. et al., Neurorehabilitation [30]
      2012, 295-301). Patients in Group 2 (20 subjects) will continue with drug therapy alone.

      For the group 1, Unified Parkinson's disease rating scale (UPDRS) II, UPDRS III, six-minute
      walking test (6MWT), Berg Balance Scale (BBS), Timed-up-and-go test (TUG), comfortable and
      fast gait speed, Self-assessment Parkinson's disease disability scale and L-dopa equivalents
      will be assessed at Baseline T0, T1 (discharge after the first MIRT cycle), T2 (control at 6
      months after discharge), T3 (hospitalization for second MIRT cycle), T4 (discharge after the
      second MIRT cycle) and T5 (end of the protocol, 18 months); For the group 2, UPDRS II, UPDRS
      III, six-minute walking test (6MWT), Berg Balance Scale (BBS), Timed-up-and-go test (TUG),
      confortable and fast gait speed, Self-assessment Parkinson's disease disability scale and
      L-dopa equivalents will be assessed at Baseline T0, T1 (check-up at 6 months), T2 (check-up
      at 12 months), T3 (check-up at 18 months).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>18 Months</target_duration>
  <primary_outcome>
    <measure>UPDRS total score</measure>
    <time_frame>18 Months</time_frame>
    <description>Unified Parkinson's Disease Rating Scale total score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>UPDRS II</measure>
    <time_frame>18 Months</time_frame>
    <description>Unified Parkinson's disease Rating Scale II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS III</measure>
    <time_frame>18 Months</time_frame>
    <description>Unified Parkinson's disease Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6MWT</measure>
    <time_frame>18 Months</time_frame>
    <description>Six Minutes Walking Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BBS</measure>
    <time_frame>18 Months</time_frame>
    <description>Berg Balance Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TUG</measure>
    <time_frame>18 Months</time_frame>
    <description>Time up and go test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGS and FGS</measure>
    <time_frame>18 Months</time_frame>
    <description>Comfortable and fast gait speed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPDDS</measure>
    <time_frame>18 Months</time_frame>
    <description>Self-Assessment Parkinson's Disease Disability Scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>L Dopa</measure>
    <time_frame>18 Months</time_frame>
    <description>levo-dopa equivalent dosage</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Rotigotine and MIRT</arm_group_label>
    <description>Group 1 - 20 Patients with PD (H&amp;Y stages 1,5-2) in therapy only with Rotigotine will undergo a Multidisciplinary intensive rehabilitation treatment (MIRT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group, only Rotigotine</arm_group_label>
    <description>Group 2 - 20 Patients with PD (H&amp;Y stages 1,5-2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multidisciplinary intensive rehabilitation treatment</intervention_name>
    <description>The first session comprises cardiovascular warm-up activities, relaxation exercises, muscle-stretching exercises, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in supine position. The second session comprises exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill plus. The last session is a session of occupational therapy aimed to improve autonomy in daily living activities.</description>
    <arm_group_label>Rotigotine and MIRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rotigotine</intervention_name>
    <description>Rotigotine 2-8 mg/24 h</description>
    <arm_group_label>Rotigotine and MIRT</arm_group_label>
    <arm_group_label>Control group, only Rotigotine</arm_group_label>
    <other_name>Dopamine agonist drug</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Parkinson's disease &quot;de novo&quot; Patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic Parkinson's disease according to Gelb et al., ability to walk without any
             physical assistance, no cognitive impairment (MMSE score &gt; 26), no comorbidity
             unrelated to Parkinson's disease, no vestibular/visual dysfunction limiting locomotor
             or balance.

        Exclusion Criteria:

          -  Atypical Parkinsonisms, cognitive impairment (MMSE &lt; 26), other comorbidities not
             related to PD, vestibular/visual dysfunction limiting locomotor or balance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Frazzitta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale generale di Zona &quot;Moriggia-Pelascini&quot;, Gravedona ed Uniti 22015 - CO, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giuseppe Frazzitta, MD</last_name>
    <phone>+39034492552</phone>
    <email>frazzittag62@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale Generale di Zona &quot;Moriggia-Pelascini&quot;</name>
      <address>
        <city>Gravedona</city>
        <state>Como</state>
        <zip>22015</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Ferrazzoli, MD</last_name>
      <phone>+39034492552</phone>
      <email>frazzittag62@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Riabilitazione Neuromotoria, Istituto Scientifico di Montescano</name>
      <address>
        <city>Montescano</city>
        <state>Pavia</state>
        <zip>27040</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Frazzitta, MD</last_name>
      <phone>+39034492552</phone>
      <email>frazzittag62@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2014</study_first_submitted>
  <study_first_submitted_qc>March 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2014</study_first_posted>
  <last_update_submitted>March 26, 2014</last_update_submitted>
  <last_update_submitted_qc>March 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rehabilitation treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotigotine</mesh_term>
    <mesh_term>Dopamine Agonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

